Concordance rates between referral and expert diagnoses according to sampling procedures in 31 138 eligible cases
| Lymphoma diagnoses . | CNB concordance . | Surgical excision concordance . |
|---|---|---|
| Overall concordance | 76.9% (n = 7627/9924) | 78.8% (n = 16 712/21 214)∗∗ |
| Classified lymphoma | 80.5% (n = 6844/8499) | 80.4% (n = 15 086/18 760) |
| Classified B-NHL | 80.2% (n = 5110/6368) | 79.2% (n = 9787/12 359) |
| DLBCL NOS | 86% (n = 2319/2698) | 82.2% (n = 3290/4001)∗∗∗ |
| TCRBCL | 72.7% (n = 40/55) | 69% (n = 78/113) |
| HGBL | 40.2% (n = 41/102) | 44.7% (n = 42/94) |
| BL | 76.6% (n = 59/77) | 81.3% (n = 78/96) |
| Grade 3B FL | 29.5% (n = 18/61) | 44.8% (n = 95/212)∗ |
| Grades 1, 2, and 3A FL | 78.1% (n = 1665/2133) | 82.6% (n = 3697/4475)∗∗∗ |
| NMZL | 63.4% (n = 192/303) | 56.8% (n = 389/685) |
| CLL/SLL | 83.2% (n = 381/458) | 79.8% (n = 1267/1587) |
| MCL | 83.4% (n = 331/397) | 80.4% (n = 761/946) |
| LPL/WD | 76.2% (n = 64/84) | 60% (n = 90/150)∗ |
| Classified PTCL | 63.5% (n = 345/543) | 62.3% (n = 980/1572) |
| PTCL NOS | 61% (n = 94/154) | 54.4% (n = 228/419) |
| AITL | 58.4% (n = 142/243) | 64.6% (n = 565/874) |
| ALCL ALK– | 68.1% (n = 49/72) | 58.0% (n = 87/150) |
| ALCL ALK+ | 81.1% ( = 60/74) | 77.5% (n = 100/129) |
| Classified HL | 87.5% (n = 1389/1588) | 89.4% (n = 4319/4829)∗ |
| cHL | 89.9% (n = 1318/1466) | 93.9% (n = 3944/4201)∗∗∗ |
| NLPHL | 58.2% (n = 71/122) | 59.7% (n = 375/628) |
| Nonlymphoid neoplasm | 65.5% (n = 93/142) | 63.6% (n = 196/308) |
| Reactive lesion | 63.6% (n = 337/530) | 69.6% (n = 1222/1756)∗∗ |
| Lymphoma diagnoses . | CNB concordance . | Surgical excision concordance . |
|---|---|---|
| Overall concordance | 76.9% (n = 7627/9924) | 78.8% (n = 16 712/21 214)∗∗ |
| Classified lymphoma | 80.5% (n = 6844/8499) | 80.4% (n = 15 086/18 760) |
| Classified B-NHL | 80.2% (n = 5110/6368) | 79.2% (n = 9787/12 359) |
| DLBCL NOS | 86% (n = 2319/2698) | 82.2% (n = 3290/4001)∗∗∗ |
| TCRBCL | 72.7% (n = 40/55) | 69% (n = 78/113) |
| HGBL | 40.2% (n = 41/102) | 44.7% (n = 42/94) |
| BL | 76.6% (n = 59/77) | 81.3% (n = 78/96) |
| Grade 3B FL | 29.5% (n = 18/61) | 44.8% (n = 95/212)∗ |
| Grades 1, 2, and 3A FL | 78.1% (n = 1665/2133) | 82.6% (n = 3697/4475)∗∗∗ |
| NMZL | 63.4% (n = 192/303) | 56.8% (n = 389/685) |
| CLL/SLL | 83.2% (n = 381/458) | 79.8% (n = 1267/1587) |
| MCL | 83.4% (n = 331/397) | 80.4% (n = 761/946) |
| LPL/WD | 76.2% (n = 64/84) | 60% (n = 90/150)∗ |
| Classified PTCL | 63.5% (n = 345/543) | 62.3% (n = 980/1572) |
| PTCL NOS | 61% (n = 94/154) | 54.4% (n = 228/419) |
| AITL | 58.4% (n = 142/243) | 64.6% (n = 565/874) |
| ALCL ALK– | 68.1% (n = 49/72) | 58.0% (n = 87/150) |
| ALCL ALK+ | 81.1% ( = 60/74) | 77.5% (n = 100/129) |
| Classified HL | 87.5% (n = 1389/1588) | 89.4% (n = 4319/4829)∗ |
| cHL | 89.9% (n = 1318/1466) | 93.9% (n = 3944/4201)∗∗∗ |
| NLPHL | 58.2% (n = 71/122) | 59.7% (n = 375/628) |
| Nonlymphoid neoplasm | 65.5% (n = 93/142) | 63.6% (n = 196/308) |
| Reactive lesion | 63.6% (n = 337/530) | 69.6% (n = 1222/1756)∗∗ |
ALCL, anaplastic large cell lymphoma; BL, Burkitt lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; HGBL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; cHL, classical HL; LPL/WD, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MCL, mantle cell lymphoma; PTCL NOS, PTCL, not otherwise specified; TCRBCL, T-cell/histiocyte-rich B-cell lymphoma.
P value significance levels: ∗≤.05; ∗∗≤.01; ∗∗∗≤.0001.